Related Experiment Video
Updated: May 25, 2025
10:21
Author Spotlight: Streamlining Protein Target Prediction and Validation via Molecular Docking and CETSA
Published on: February 23, 2024
2.3K
Integrated Computational and Experimental Insights Into MEK1/2 Inhibitors: Structural Validation, Docking, ADMET,
Rohit Pal1, Gurubasavaraja Swamy Purawarga Matada1, Ghanshyam Teli2
1Integrated Drug Discovery Centre, Department of Pharmaceutical Chemistry, Acharya and BM Reddy College of Pharmacy, Bengaluru, Karnataka, India.
Chemistry & Biodiversity
|February 27, 2025
Summary
This study identifies RO5126766 as a potent MEK1/2 inhibitor for cancer therapy. Computational and in vitro analyses confirm its efficacy against aggressive and treatment-resistant cancers.
Area of Science:
- Medicinal Chemistry
- Computational Biology
- Oncology
Background:
- The MAPK pathway is crucial in cancer progression.
- Novel MEK1/2 inhibitors are needed for targeted cancer therapy.
Purpose of the Study:
- To explore the therapeutic potential of novel MEK1/2 inhibitors.
- To evaluate RO5126766 as a lead compound for cancer treatment.
Main Methods:
- Integrated computational approach: molecular docking, pharmacophore modeling, molecular dynamics, DFT analysis.
- In vitro anticancer assays on MCF-7, MDA-MB-231, and A549 cell lines.
- ADMET and MEP analysis for pharmacological properties.
Main Results:
- RO5126766 showed high binding affinity to MEK1/2 (-10.1 to -9.5 kcal/mol).
- Simulations confirmed complex stability (RMSD 0.95-4.22 Å).
- RO5126766 exhibited potent in vitro anticancer activity (nM IC50 values) and favorable ADMET properties.
Conclusions:
- RO5126766 is a potent and selective MEK1/2 inhibitor.
- Demonstrates significant potential as a targeted therapeutic agent for aggressive and treatment-resistant cancers.
More Related Videos
Related Concept Videos
02:15M-Cdk Drives Transition Into Mitosis
5.5K
Checkpoints throughout the cell cycle serve as safeguards and gatekeepers, allowing the cell cycle to progress in favorable conditions and slow or halt it in problematic ones. This regulation is known as the cell cycle control system.
Cyclin-dependent kinases, or Cdks, work in concert with cyclins to control cell cycle transitions. M-Cdk, a complex of Cdk1 bound to M cyclin, is a well-known example of this coordinated control that drives the transition from the G2 to the M phase.
M cyclin...
Cyclin-dependent kinases, or Cdks, work in concert with cyclins to control cell cycle transitions. M-Cdk, a complex of Cdk1 bound to M cyclin, is a well-known example of this coordinated control that drives the transition from the G2 to the M phase.
M cyclin...
5.5K
02:38Mitogens and the Cell Cycle
6.4K
Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
6.4K